

## Appendix 2: ADULT ACUTE MYELOID LEUKAEMIA (AML)

Approved settings/ treatment line	Protocols	Evidence level
APL Induction/ Low risk	ATRA + Arsenic trioxide	Category 1, Preferred
	ATRA + Idarubicin	Category 1, Preferred, Arsenic trioxide contraindication
APL Consolidation/ Low risk	ATRA + Arsenic trioxide	Category 1, Preferred
	ATRA+ Idarubicin+ Mitoxantrone	Category 1, Preferred
APL Induction/ High risk	ATRA+ Idarubicin+ Arsenic trioxide	Category 2A, Preferred
	ATRA+ Arsenic trioxide+ Gemtuzumab ozogamycin	Category 2A, Preferred
	ATRA+ Daunorubicin+ Cytarabine	Category 2A
	ATRA+ Idarubicin	Category 2A
APL Consolidation/ High risk	ATRA+ Arsenic trioxide+ Gemtuzumab ozogamycin	Category 2A
	ATRA+ Arsenic Trioxide	Category 2A
	ATRA+ Arsenic Trioxide+ Daunorubicin	Category 2A
	Daunorubicin+ Cytarabine	Category 2A
	ATRA+ Cytarabine+ Idarubicin+ Mitoxantrone	Category 2A
APL Induction/ High risk with cardiac issues	ATRA+ Arsenic trioxide+ Gemtuzumab ozogamycin	Category 2A
	ATRA+ Gemtuzumab ozogamycin	Category 2A
APL Consolidation/ High risk with cardiac issues	Anthracyclines + ATRA (If no previous exposure to Anthracyclines)	Category 2A
	Arsenic trioxide ± ATRA ± Gemtuzumab ozogamycin (If no previous exposure to Arsenic trioxide)	Category 2A
	Arsenic Trioxide ± ATRA ± (Anthracyclines or Gemtuzumab ozogamycin) in case of late relapse > 6 months.	Category 2A
AML Induction, < 60 years	(3+7) Regimen (Cytarabine + Idarubicin or Daunorubicin)	Category 1
	(3+7) Regimen + Gemtuzumab ozogamycin	Category 2A, CD 33+ve
	(3+7) Regimen + Cladribine	Category 2A, Poor risk
	High dose Cytarabine (HiDAC) + Idarubicin or daunorubicin.	Category 1 (<45 y), Category 2B (others)
	Fludarabine + HiDAC + Idarubicin + GCSF	Category 2B
AML Post-remission therapy, < 60 years	HiDAC ± Gemtuzumab ozogamycin (CD 22 +ve)	Category 2A
	Cytarabine + Daunorubicin + Gemtuzumab ozogamycin (CD 22+ve)	Category 2A
	HiDAC	Category 1
AML Intensive induction ≥ 60 years	(3+7) Regimen.	Category 2A
	(3+7) Regimen + Gemtuzumab ozogamycin (CD 22+ve)	Category 2A
	Venetoclax + Azacitidine	Category 2A
	Venetoclax + Low-dose Cytarabine	Category 2A
	Azacitidine	Category 2B



Approved settings/ treatment line	Protocols	Evidence level
<b>AML Non-Intensive induction ≥ 60 years</b>	Venetoclax + Azacitidine	Category 2A, Preferred
	Venetoclax + Low-dose Cytarabine	Category 2A, Preferred
	Azacitidine	Category 2A
	Gemtuzumab ozogamycin (CD 22+ve)	Category 2B
	Azacitidine + Sorafenib (FLT-3 ITD +ve)	Category 2A
<b>AML Post-remission therapy, &lt; 60 years</b>	St. dose Cytarabine ± Anthracyclines.	Category 2A
	Intermediate dose Cytarabine.	Category 2A
	Cytarabine + Daunorubicin + Gemtuzumab ozogamycin (CD 22+ve)	Category 2A
	Azacitidine	Category 2A
<b>Relapsed/ Refractory AML, (Target therapy)</b>	Gemtuzumab ozogamycin (CD 22 +ve)	Category 2A
<b>Relapsed/ Refractory AML (Intensive therapy)</b>	Cladribine + Cytarabine + GCSF ± Idarubicin/ Mitoxantrone	Category 2A
	Fludarabine + Cytarabine + GCSF ± Idarubicin	Category 2A
	Etoposide + Cytarabine ± Mitoxantrone	Category 2A
	HiDAC ± Anthracyclines (If not previously used)	Category 2A
<b>Relapsed/ Refractory AML (Non-Intensive)</b>	Azacitidine	Category 2A
	Low-dose Cytarabine (LDAC)	Category 2B
	Venetoclax + Azacitidine or LDAC	Category 2A